Year: 2023

Avistone_Logo

Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BEIJING, China--(BUSINESS WIRE)--Avistone Biotechnology Co., Ltd (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today...

Shaperon_CI.png

Shaperon Inc. Makes a Splash at BioFutureâ„¢ 2023 With the Announcement of US Subsidiary Hudson Therapeutics Inc. and Positive Clinical Data

CAMBRIDGE, Mass. & SEOUL, South Korea--(BUSINESS WIRE)--Shaperon Inc. grabbed the spotlight at BioFutureâ„¢ 2023 as it confidently graced the stage,...

GENOMEINSIGHT_Logo

Genome Insight, Inc. Announces Groundbreaking Research Collaboration with Shriners Children’s for Patients with Adolescent Idiopathic Scoliosis

Project aims to unravel the genetic etiology of Adolescent Idiopathic Scoliosis (AIS) by leveraging Genome Insight’s whole-genome sequencing analysis and...